Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Xyzal OTC Antihistamine Claims Lose Second Challenge In Six Months

Jul 24 2018

• By Eileen Francis

Related Content

Sanofi’s <i>Allegra</i> Claims Clear NAD Review In Merck’s Second Challenge

Oct 31 2011

<em>Xyzal</em> Claim To Match <em>Zyrtec</em> Efficacy At Half Dosage Dissolves In NAD Review

Feb 02 2018

Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine

Feb 02 2017

Related Companies

Sanofi

Bayer AG

Additional Topics

United States Advertising, Marketing & Sales OTC Drugs Respiratory Consumer

More from Marketing & Advertising

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window